NEW YORK, USA AND ABU DHABI, UAE, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Sherlocq, the first AI-native regulatory intelligence platform for global financial services, today announced its public launch. Designed for compliance officers, lawyers, risk professionals, and regulators who operate at the intersection of law, governance, and institutional accountability, Sherlocq delivers regulatory intelligence that is precise, traceable, and usable at institutional scale.The launch marks the emergence of a new category in enterprise AI: regulatory intelligence, a vertical distinct from generic AI assistants, conventional regtech monitoring tools, and document management platforms. Sherlocq has been built from the ground up to meet the security, privacy, and domain standards that regulated institutions require, and which no general-purpose AI platform has been designed to deliver.THE PROBLEMFinancial institutions, law firms, regulators, and consultants collectively spend over $300 billion every year on regulatory compliance. More than ten million professionals carry the weight of that complexity daily, tracking regulatory changes across dozens of jurisdictions, reviewing thousands of documents, and making high-stakes decisions that can determine the fate of institutions and individuals alike.Until now, the tools available have been fundamentally inadequate: monitoring without interpretation, alerts without answers, search without synthesis. Regulatory research has remained a largely manual process for decades. Vertical AI has already demonstrated category-defining value in adjacent domains. Regulatory intelligence represents a larger, more global, and more complex opportunity.Sherlocq changes that.THE PLATFORMAt launch, Sherlocq covers the regulatory output of governments, supervisory authorities, and enforcement bodies across 30+ jurisdictions, including the US, UK, UAE, Singapore, and Hong Kong. It ingests, structures, and indexes this information continuously, so when a compliance officer, lawyer, or risk professional asks a question, Sherlocq returns a precise, sourced, and traceable answer in seconds. Research that previously required hours of manual work across multiple sources is completed in under a minute.The platform launches with three live capabilities:Regulatory Research and Analysis - Multi-jurisdiction research, cross-border regulatory comparison, compliance framework analysis, and obligation mapping across the full spectrum of financial services regulation, covering all major regulated financial centres.Document Intelligence - Structured review, gap assessment, benchmarking, and policy analysis against applicable regulatory standards, available on the native Sherlocq platform.Sanctions Intelligence - Real-time, multi-regime sanctions research across OFAC, OFSI, EU, UAE, and 320+ data sources in a single query, with full source traceability. The first AI-native platform to deliver this level of depth and auditability across multiple sanctions regimes simultaneously.Sherlocq is available on web, iOS, and Android, for individual professionals and enterprise organisations. AI connectors are live for Claude and ChatGPT, enabling regulatory research to be accessed directly within the tools professionals already use. Microsoft Copilot and Google Gemini integrations follow shortly.Sherlocq is certified to ISO 27001 and ISO 27701 standards, meeting the security and data privacy requirements of regulated financial institutions globally.FOUNDER'S STATEMENT"I have spent my career sitting across the table from regulators, leading investigations at the highest levels, and advising institutions in the most consequential moments of their existence. In every one of those engagements, the same problem recurred: brilliant professionals, at world-class institutions, spending most of their time on research and cross-referencing that should have been automated years ago. Not because the technology did not exist. Because no one had built it with the rigour, the domain depth, and the institutional trust that this work demands. That is what we built. Sherlocq is not a general AI tool adapted for compliance. It is the intelligence infrastructure that this industry has always needed and never had," said Bhavin Shah, Founder and Chief Executive Officer, Sherlocq.ABOUT THE FOUNDERBhavin Shah is a globally recognised regulatory and compliance leader with over twenty years of experience advising sovereigns, regulators, boards, and financial institutions across their most complex and politically sensitive challenges. His career spans multi-jurisdiction investigations, AML and financial crime reform, regulatory negotiations, crisis management, and governance advisory across the US, UK, Middle East, and Asia Pacific. He has advised some of the world's most consequential regulatory reform processes and financial institutions at moments of institutional stress, enforcement risk, and strategic transformation.Shah is a World Economic Forum Young Global Leader (2020), a board member of the D2A2 digital assets and AI policy forum, and holds executive education credentials from Harvard Business School and Harvard Kennedy School. He serves as an independent non-executive director on the boards of regulated financial institutions, giving him direct and ongoing insight into the governance, compliance, and regulatory pressures that Sherlocq is designed to address.INDUSTRY VOICES"Regulatory complexity has been accelerating for years and this is only compounding with the recent trends toward fragmentation around the globe. The tools available to compliance professionals have not kept pace. Sherlocq addresses that gap in a way that is substantive, not superficial. What distinguishes this platform is that it has been built with a genuine understanding of how regulated institutions work and what they actually need to be more effective and more efficient. The depth, the traceability, and the institutional-grade approach reflect the kind of rigour that regulators and boards rightly expect. I am proud to support Bhavin and the Sherlocq team as they bring this important product to market," said Bryan Stirewalt, Former Chief Executive, Dubai Financial Services Authority; Former National Bank Examiner, Office of the Comptroller of the Currency; Board Advisor, Sherlocq."Running a banking group across more than 35 markets meant living with regulatory complexity as a daily operational reality. Our teams were talented and diligent but the tools available forced them into a process that was slow, fragmented and heavily manual. Sherlocq solves that problem. It gives compliance and legal professionals the structured multi-jurisdictional intelligence that I would have wanted for my team. This is the platform the industry has always needed,” said Arnold Ekpe, Former Group Chief Executive Officer, Ecobank Group; Board Advisor, Sherlocq.ABOUT SHERLOCQSherlocq Inc. is a US-incorporated AI technology company (Delaware) with principal offices in New York and Abu Dhabi, UAE, and the creator of the first AI-native regulatory intelligence platform purpose-built for global financial services. The company has completed a pre-seed financing round backed by investors across the US, UAE, and Europe. Designed for compliance officers, lawyers, risk professionals, regulators, and governance teams, the platform delivers multi-jurisdiction regulatory research, document intelligence, and sanctions intelligence, with workflow automation and deeper enterprise capabilities on the near-term roadmap. Sherlocq is certified to ISO 27001 and ISO 27701 standards and is available globally on web, iOS, and Android. Financial institutions, law firms, and professional services organisations seeking enterprise access are invited to contact hello@sherlocq.com. sherlocq.com | sherlocq.ai | hello@sherlocq.com MEDIA CONTACTFor media enquiries, interview requests with Bhavin Shah, or access to additional materials including product demonstrations, founder biography, and platform assets:Press contact: press@sherlocq.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BILLUND, DENMARK, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At the LEGO Foundation's annual meeting, the Board of Directors elected Agnete Kirk Kristiansen as Chair of the Board. As fourth generation member of the Kirk Kristiansen family, owners of the LEGO Group, she becomes only the fifth Chair of the Foundation since it was founded in 1986.Agnete Kirk Kristiansen has served as Deputy Chair of the LEGO Foundation since 2023 and replaces her brother Thomas Kirk Kristiansen who steps down to assume the position of Deputy Chair. In addition to her role at the LEGO Foundation, Agnete Kirk Kristiansen also serves as Deputy Chair of KIRKBI A/S, the family-owned holding and investment company that owns 75% of the LEGO Group.As ascending Chair, Agnete Kirk Kristiansen highlighted the role of the LEGO Foundation in building a brighter tomorrow for children around the world:I am truly honored to step into the role as Chair of the LEGO Foundation and to continue our important work for children. The foundation holds a very special place in our family and has done so ever since it was established more than 40 years ago. A deep sense of responsibility to make a positive difference for children runs through our family and I strongly believe that every child should have the opportunity to thrive and grow. I am proud to contribute to this mission and help carry it forward.The change in chair takes place the year after Agnete stepped into the role as chair of non-profit foundation Ole Kirk's Fond. With the transition, the fourth generation of the owner family is broadening its engagement and commitment to active ownership.Descending Chair Thomas Kirk Kristiansen said:It has been a privilege to chair the LEGO Foundation for the past 10 years, and I am very happy to now pass on the role to Agnete. She is deeply committed to the LEGO Foundation mission, and I know she will do her utmost to further the cause of securing a childhood for all. During her tenure as Deputy Chair, she has played an integral part in shaping the foundation's current strategy and as she steps into the role as Chair, we further widen the active ownership and engagement from the family across the LEGO ecosystem.Thomas Kirk Kristiansen has served as Chair of the LEGO Foundation since 2016 and in that period the foundation has committed grants of more than DKK 15 billion (EUR 2 billion) through partner organisations across the globe to improve children's outcomes.For 40 years, the LEGO Foundation has been focused on giving back and building a better world for children. We are very mindful of the trust families and communities place in us, and it is not a responsibility we take lightly. Even in the most challenging settings, the foundation can help put a smile on a child's face, lift up learners of all abilities and change life paths. We do so with the utmost sensitivity and responsibility, said Agnete Kirk Kristiansen.In addition to safeguarding the continued development and success of the LEGO Group as part-owner, the LEGO Foundation pursues its philanthropic mission to support initiatives within education, research, and child development through funding of and close collaboration with organisations such as Brac, IRC, UNICEF, Save the Children, Norwegian Refugee Council and others.Further changes to the LEGO Foundation BoardIn addition to Agnete and Thomas Kirk Kristiansen changing roles as Chair and Deputy Chair, the LEGO Foundation Board of Directors at its May meeting also elected as member of the Board Ingrid Stange, who brings a wealth of experience in philanthropy, education and non-profit leadership. Further, both Jørgen Vig Knudstorp, former CEO of the LEGO Group, and El Hadji Amadou Gueye Sy (As), former Secretary-General of the International Federation of Red Cross and Red Crescent Societies, left the Board after 16 and four years of service respectively to the LEGO Foundation.Thomas Kirk Kristiansen thanked the two departing Board members for their long-standing commitment to the foundation:We look very much forward to welcoming Ingrid, who brings highly complementary expertise to the board. At the same time, I thank As for bringing invaluable insights and experience to help shape our work.I would also like to extend my sincerest gratitude to Jørgen for his unwavering dedication to the foundation. During his extensive tenure, Jørgen has been instrumental in defining our vision and strategy while never losing sight of the children we are here to serve.Additionally, Malou Aamund, who has served on the Board since 2021, stepped into the role of Second Deputy Chair of the Foundation.Biography: Agnete Kirk KristiansenLEGO Foundation2026 - Chair of the Board of Directors2023 - 2026 Second Deputy Chair of the Board of DirectorsFrom 2008 Member of the Board of DirectorsKIRKBI A/S2024 - Deputy Chair of the BoardCentre for ADHD+, Aarhus, DenmarkFounderOle Kirk's Fond2025 - Chair of the BoardDegreePsychology, Aarhus University, 2010Additional roles, present and past:Executive Manager, KIRK83 Holding ApSMember of the Advisory Board, RucaRepresentative of the fourth generation of the LEGO owner familyExtensive experience in family-owned companies, long-term stewardship and board workLEGO Foundation Board of DirectorsAgnete Kirk Kristiansen - ChairThomas Kirk Kristiansen - First Deputy ChairMalou Aamund - Second Deputy ChairHilary Pennington - Member of the BoardIngrid Stange - Member of the BoardLEGO Foundation Board of Directors Chairs1986 - 1993: Gotfred Kirk Kristiansen (2nd-generation LEGO owner)1993 - 2000: Bent Skov2000 - 2016: Kjeld Kirk Kristiansen (3rd-generation LEGO owner)2016 - 2026: Thomas Kirk Kristiansen (4th-generation LEGO owner)2026 - Agnete Kirk Kristiansen (4th-generation LEGO owner)About LEGO Fonden:The LEGO Foundation is a Danish corporate foundation entrusted with 25 % ownership of the LEGO Group. The Foundation works with partners around the world to support children's needs and champion the dignity of childhood. Through both philanthropic donations and impact investments the Foundation exists to build the conditions and create the space for every child, everywhere, to thrive and grow. More information about the LEGO Foundation can be found at: https://www.legofoundation.com/Contact information:Mads Hvitved Grandmads.hvitved.grand@legofoundation.comSOURCE: LEGO Fonden Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重点：· 根据第三方行业报告，随着医疗服务提供者持续向价值导向型和居家护理模式转型，美国远程患者监测（RPM）市场目前规模已达140亿美元，预计到2030年将达到约290亿美元，复合年增长率（CAGR）为12.6%¹· 通过其MSO基础设施，在多家医疗机构启动了试点项目，重点关注慢性病管理（CCM）和远程患者监测（RPM）· 截至目前，通过该试点基础设施已产生约1,500余份理赔，且扩展路线图旨在覆盖更多医疗服务提供者· Wellgistics药房网络拥有6,500多家独立药房，可为患者参与和护理协调计划提供支持· 参与该计划的药剂师有望获得新的临床服务收入机会佛罗里达州坦帕市, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 领先的医疗科技与药品分销公司 Wellgistics Health, Inc.（纳斯达克代码：WGRX）（以下简称“Wellgistics”或“公司”）今日宣布，将与 Kare PharmTech 和 Kare Clinicals 开展试点合作，整合其管理服务组织（MSO）基础设施，以支持参与该计划的医疗机构开展慢性病管理（“CCM”）和远程患者监测（“RPM”）服务。据第三方行业报告显示，随着医疗服务提供者持续向价值导向型和居家护理模式转型，美国远程患者监测市场目前规模为140亿美元，预计到2030年将达到约290亿美元，复合年增长率（CAGR）为12.6%。¹该试点项目目前涵盖多家医疗机构，由 Kare Clinicals MSO 代表参与的医疗机构及服务提供方负责账单处理。该计划旨在通过可扩展的运营流程和技术驱动的工作流，支持患者参与、护理协调及纵向监测项目。所有慢性病管理（CCM）和远程患者监测（RPM）服务均应由持有相应执照的医疗服务提供方及参与实体，根据适用的联邦和州医疗保健法律、报销要求以及支付方项目规则提供并进行结算。双方公司表示，试点基础设施已产生1,500多份索赔，并计划以此为基础，逐步扩大服务范围，未来将覆盖更多医疗服务提供者。作为合作的一部分，Wellgistics Health计划利用其覆盖6,500多家独立药房的网络，协助识别并支持可能从CCM和RPM服务中获益的符合条件患者。Wellgistics药房网络内的参与药房还可能有机会参与与该项目相关的临床参与计划。Wellgistics Health, Inc.总裁兼首席执行官Prashant Patel表示：“我们相信，药房参与、医疗服务提供者互联以及技术赋能的护理协调三者的融合，为改善患者预后创造了重要机遇，同时为独立药房开辟了新的经济机遇。通过与 Kare PharmTech 的此次试点合作，我们正在建立一套基础设施，旨在支持慢性病管理及远程患者监测项目中可扩展的患者参与模式。”Kare PharmTech 创始人兼首席执行官米塔尔·帕内拉补充道：“我们一直致力于构建一个运营高效的 MSO 平台，能够为医疗服务提供者提供护理协调和报销工作流支持。通过与Wellgistics Health及其药房网络合作，我们相信能够进一步扩大患者参与度、提升护理连续性，并为未来医疗服务提供者的业务增长构建可扩展的框架。”双方指出，随着扩展工作的持续推进，该试点项目仍需根据运营发展、医疗服务提供者的参与情况以及合规要求进行动态调整。关于 Wellgistics Health, Inc.Wellgistics Health（纳斯达克代码：WGRX）是一家健康信息技术领域的领导者，将专有的药房配药优化人工智能平台EinsteinRx™整合到其获得专利的基于区块链的智能合约平台PharmacyChain™中，以优化处方药配药流程。其集成平台连接了 6,500 多家药房（“Wellgistics 药房网络”）和 200 多家制造商，提供批发分销、数字处方路由、直接送达患者以及由人工智能驱动的枢纽服务，例如资格审核、用药依从性管理、新用户注册、预授权以及按需现金支付履约服务，以优化患者的用药获取渠道。Wellgistics 提供端到端解决方案，旨在为美国独立药房恢复处方药市场的可及性、透明度和信任。关于 Kare PharmTech, LLCKare Clinicals 隶属于 Kare PharmTech, LLC 旗下的企业生态系统，而 Kare PharmTech, LLC 由基兰·帕特尔（Kiran Patel）博士控制。帕特尔博士于 1992 年创立了医疗补助计划（Medicaid）服务提供商 WellCare，并于 2002 年以 2 亿美元的价格将其出售。2007年，帕特尔博士创立了America's 1st Choice Holdings，并收购了Freedom Health和Optimum Holdings。2017年，他将America's 1st Choice Holdings出售给Anthem, Inc.。帕特尔博士是一位知名慈善家，曾被《佛罗里达趋势》杂志评为“年度佛罗里达人”。前瞻性陈述本新闻稿包含《1995年私人证券诉讼改革法案》所界定的前瞻性陈述。前瞻性陈述包括关于本公司预期、信念、计划、目标、意图、战略、未来事件或业绩的陈述，包括关于与 Kare PharmTech 和 Kare Clinicals 开展试点合作所带来的潜在效益、可扩展性、扩展、商业化、服务提供商参与、报销机会、患者参与计划、运营能力及未来发展的陈述，以及 Wellgistics 药房网络在支持 CCM 和 RPM 计划方面预计将发挥的作用。诸如“预期”、“相信”、“可能”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“寻求”、“应当”、“将”等词语及类似表述旨在识别前瞻性陈述。这些前瞻性陈述基于当前的预期和假设，涉及可能导致实际结果与这些陈述所表达或暗示的结果存在重大差异的风险和不确定性。此类风险和不确定性包括但不限于：与医疗服务提供者的采用和参与相关的风险、报销结果、患者参与度、运营执行、试点项目的可扩展性、监管和医疗保健合规性考虑、适用法律或报销政策的变更、市场对公司服务的接受度、竞争因素，以及公司建立和维持战略关系并成功实施其业务战略的能力。本新闻稿所述的试点合作具有探索性质，无法保证该举措将带来更广泛的商业关系、重大的收入机会或长期的运营成功。有关这些及其他风险的更多信息，可查阅本公司向美国证券交易委员会提交的文件，包括其中所载的风险因素。除法律要求外，本公司不承担因新信息、未来事件或其他原因而更新或修订任何前瞻性陈述的义务。Wellgistics 媒体与投资者联系方式媒体：media@wellgisticshealth.com投资者关系：IR@wellgisticshealth.com[1] MarketsandMarkets - 美国远程患者监测市场报告来源：Wellgistics Health, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd. (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 近日，标普全球（S&P Global）在其发布的最新简报中明确表示，预计国泰海通集团下属公司国泰君安国际控股有限公司（“国泰君安国际”、“公司”，股份代号：1788.HK）及其直接控股公司国泰海通金融控股有限公司（“国泰海通金控”）作为母公司国泰海通证券股份有限公司（“国泰海通”）核心子公司，将继续在集团国际化战略中发挥关键作用。标普全球在简报中指出，国泰君安国际与母公司在投资银行及财富管理领域的业务协同效应显著，进一步强化了其在集团内部的重要性。国际化发展为国泰海通的核心战略重点之一，国泰君安国际将继续在集团加强全球布局的过程中扮演关键角色。2025年，国泰君安国际及国泰海通金控分别实现利润增长284%及85%，分别占国泰海通证券当年净利润约3%及8%。这一强劲的财务表现，有力印证了公司对集团整体业务发展的贡献。标普全球预期，国泰君安国际未来两年仍将作为集团核心子公司之一，持续获得母公司支持，其发行人信用评级及“稳定”展望将与母公司保持同步。标普全球认为，公司可获得母公司稳定、及时的支持，包括在必要时通过国泰海通间接受益于上海政府的资源。这份简报充分反应了公司的现况及对未来发展的预期。国泰君安国际将坚定不移地配合集团国际化战略，持续提升自身的专业能力及与集团的业务协同效率，为国泰海通集团成为具备国际竞争力与市场引领力的一流投资银行作出贡献。注：本文内容基于标普全球评级于2026年5月5日发布的独立观点文件（Tear Sheet：Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.），该文件不构成评级行动。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK），是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高质量、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予“Baa2”及“BBB+”长期发行人评级，MSCI ESG“AAA”评级, Wind ESG“A”评级及商道融绿ESG“A”评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的信息请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.” Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ORLANDO, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers,‘almost right’just isn’t good enough,” said Christian Klein, CEO of SAP SE,“By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麦比隆, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 在乐高基金会年度会议上，董事会选举阿格妮特·柯克·克里斯蒂安森担任董事会主席。作为乐高集团所有者柯克·克里斯蒂安森家族的第四代成员，她成为该基金会自1986年成立以来仅有的第五位主席。阿格妮特·柯克·克里斯蒂安森自2023年起担任乐高基金会副主席，此次接替其兄长托马斯·柯克·克里斯蒂安森出任主席，后者卸任后将担任副主席。除在乐高基金会的职务外，阿格妮特·柯克·克里斯蒂安森还担任家族控股及投资公司KIRKBI A/S的副主席，该公司持有乐高集团75%的股份。作为新任主席，阿格妮特·柯克·克里斯蒂安森强调了乐高基金会在为全球儿童创造更美好未来方面所发挥的作用：· “能够接任乐高基金会主席一职，并继续我们为儿童开展的重要工作，我深感荣幸。自40多年前成立以来，该基金会在我们家族中一直占据着非常特殊的地位。为儿童创造积极影响的深切责任感贯穿于我们家族的始终，我坚信每个孩子都应有机会茁壮成长。我为能为这一使命贡献力量并助力其传承而感到自豪。此次主席交接发生在阿格妮特接任非营利基金会“奥勒·柯克基金会”（Ole Kirk's Fond）主席一职的次年。随着这一交接，家族第四代成员正进一步拓展其参与范围，并致力于践行积极所有权。卸任主席托马斯·柯克·克里斯蒂安森表示：· 过去10年担任乐高基金会主席是我莫大的荣幸，如今能将这一职责移交给阿格妮特，我感到非常高兴。她对乐高基金会的使命怀有深切的热忱，我相信她将竭尽全力，为“保障所有儿童的童年”这一事业贡献力量。“在担任副主席期间，她为制定基金会当前的战略发挥了关键作用。随着她接任主席一职，我们将进一步扩大家族在整个乐高生态系统中的积极所有权和参与度。”托马斯·柯克·克里斯蒂安森自2016年起担任乐高基金会主席，在此期间，基金会通过全球合作伙伴组织承诺拨款超过150亿丹麦克朗（20亿欧元），致力于改善儿童福祉。· “40年来，乐高基金会始终致力于回馈社会，为儿童构建更美好的世界。我们深知家庭和社区对我们的信任，这份责任我们绝不轻视。即使在最艰难的环境中，基金会也能帮助孩子们展露笑颜，激励不同能力水平的学习者，并改变他们的人生轨迹。我们将以最敏锐的洞察力和最负责任的态度践行这一使命，”阿格妮特·柯克·克里斯蒂安森表示。作为乐高集团的股东之一，乐高基金会不仅致力于保障集团的持续发展与成功，更通过资助并紧密合作于Brac、IRC、联合国儿童基金会、救助儿童会、挪威难民理事会等组织，践行其慈善使命，支持教育、研究及儿童发展领域的各项倡议。乐高基金会董事会其他变动除阿格妮特与托马斯·柯克·克里斯蒂安森分别担任主席和副主席外，乐高基金会董事会还在5月的会议上选举英格丽德·斯坦格为董事会成员，她拥有丰富的慈善、教育及非营利组织领导经验。此外，乐高集团前首席执行官约尔根·维格·克努德斯托普（Jørgen Vig Knudstorp）以及红十字会与红新月会国际联合会前秘书长埃尔·哈吉·阿马杜·盖耶·西（El Hadji Amadou Gueye Sy，简称As），在为乐高基金会服务16年和4年后，分别离开了董事会。托马斯·柯克·克里斯蒂安森（Thomas Kirk Kristiansen）对两位离任的董事会成员长期以来对基金会的奉献表示感谢：· 我们非常期待欢迎英格丽德的加入，她将为董事会带来高度互补的专业知识。同时，我感谢阿斯（As）为我们提供了宝贵的见解和经验，帮助塑造了我们的工作。· 我还要向约尔根表达最诚挚的谢意，感谢他对基金会的坚定奉献。在任职期间，约尔根在制定我们的愿景和战略方面发挥了关键作用，同时始终没有忘记我们所服务的儿童。此外，自2021年起担任董事会成员的玛露·阿蒙德，接任了基金会第二副主席的职务。个人简介：阿格内特·柯克·克里斯蒂安森乐高基金会2026年 - 董事会主席2023年至2026年 - 董事会第二副主席2008年起 - 董事会成员KIRKBI A/S2024年 - 董事会副主席ADHD+中心，丹麦奥胡斯创始人奥勒·柯克基金会2025年 - 董事会主席学历2010年，奥胡斯大学心理学专业其他现任及曾任职务：· KIRK83 Holding ApS 执行经理· Ruca 顾问委员会成员· 乐高所有者家族第四代代表· 在家族企业、长期管理及董事会工作中拥有丰富经验乐高基金会董事会阿格内特·柯克·克里斯蒂安森 - 主席托马斯·柯克·克里斯蒂安森 - 第一副主席马洛·阿蒙德 - 第二副主席希拉里·彭宁顿 - 董事会成员英格丽德·斯坦格 - 董事会成员乐高基金会董事会主席1986 - 1993：戈特弗雷德·柯克·克里斯蒂安森（乐高第二代所有者）1993 - 2000：本特·斯科夫2000 - 2016：凯尔德·柯克·克里斯蒂安森（乐高第三代所有者）2016 - 2026：托马斯·柯克·克里斯蒂安森（乐高第四代所有者）2026 - 阿格妮特·柯克·克里斯蒂安森（乐高第四代所有者）关于乐高基金会：乐高基金会是一家丹麦企业基金会，受托持有乐高集团25%的股权。该基金会与全球合作伙伴携手，致力于满足儿童需求，捍卫童年的尊严。通过慈善捐赠和影响力投资，该基金会致力于为世界各地的每个孩子创造茁壮成长的条件和空间。有关乐高基金会的更多信息，请访问： https://www.legofoundation.com/ 联系方式：马德斯·赫维特·格兰德mads.hvitved.grand@legofoundation.com 来源：乐高基金会 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务撮要截至2026年3月31日止三个月(百万港元)20262025变动收入 1,115.61,071.9+ 4.1%毛利402.1376.1+ 6.9%毛利率36.0%35.1%+ 0.9个百分点本公司拥有人应占溢利122.4110.0+ 11.3%纯利率11.0%10.3%+ 0.7个百分点经调整EBITDA209.0201.5+ 3.7%每股盈利（港仙）11.7310.54+ 11.3%香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）今天公布截至2026年3月31日止三个月（「报告期」）之未经审核第一季度财务业绩。报告期内，集团录得收入1,115.6百万港元，较2025年同期的1,071.9百万港元增加4.1%。毛利按年上升6.9%至402.1百万港元，主要由于持续实施成本效益措施所致。毛利率由2025年同期的35.1%增加0.9个百分点至36.0%，主要由于核心品牌销量增加，消化了成本压力。本公司拥有人应占溢利录得122.4百万港元，按年显著上升11.3%；经调整EBITDA则按年增长3.7%至209.0百万港元。来自香港及其他地区业务的收入增加3.1%，此乃由于面类业务表现稳健，特别是集团核心品牌合味道及出前一丁。内地业务收入增加4.6%，主要受惠于内陆地区的销售扩大及人民币兑港元升值所致。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示：「延续2025年建立的良好增长势头，集团于本季度持续录得稳健的业务表现，主要市场的营运表现保持平稳。收入及盈利按年有所提升，主要受稳定的销售量所支持。核心方便面业务于各地区持续表现理想，而高端化及多元化策略亦于中国内地进一步取得成效。凭借均衡的地域布局及持续提升的营运执行力，集团有信心为股东创造可持续的长远价值。」有关日清食品有限公司日清食品有限公司（「日清食品」，连同其附属公司统称「集团」；股份代号：1475）为一间在中国内地及香港知名的食品公司，主要专营优质方便面市场，旗下众多品牌不仅知名度高，且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」，以及多元化的家庭食品品牌组合，出品具标志性和优质的方便面、优质冷冻食品（包括冷冻点心及冷冻面条）并销售和分销其他食品及饮料产品（包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品）。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面，集团以创新技术推出「ECO杯」概念，销售活动主要集中在中国内地的一线及二线城市。此外，日清食品在其他地区开展业务，包括越南、台湾、韩国及澳洲市场。日清食品被纳入5项恒生指数，包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通食品饮料消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司（"中国抗体"或"公司"，连同旗下附属公司统称"集团"，股份代号：03681.HK）欣然宣布，公司执行董事、主席兼首席执行官梁瑞安博士作为特邀嘉宾，出席了近日在英国伦敦举办的2026 LifeArc转化科学峰会（LifeArc Translational Science Summit）。作为转化医学领域具有全球影响力的盛会之一，本届峰会汇聚了来自世界各地的顶尖科学家、临床医师、行业领袖、政策制定者及投资机构。梁瑞安博士在峰会中发表了主旨报告，系统分享了中国抗体在自身免疫疾病领域的研发策略与核心管线的最新临床进展，并与国际同行展开深入交流。本届峰会由英国知名医学研究慈善机构LifeArc主办。LifeArc长期致力于推动早期科学研究向临床应用的转化，尤其在罕见病及未满足医疗需求领域具有深远影响力。峰会聚焦转化研究如何通过推进新型治疗手段、重塑临床实践、影响卫生政策及驱动商业创新，加速从实验室发现到惠及患者的全过程。与会嘉宾围绕抗体药物、基因治疗、细胞治疗等前沿领域展开跨学科对话，探讨如何破解转化医学中的关键瓶颈，促进产学研医协同发展。梁瑞安博士的受邀，标志着中国抗体在创新免疫治疗领域的探索已获得国际权威机构的高度关注。在峰会主题报告中，梁瑞安博士深入剖析了全球自身免疫疾病药物研发的格局与挑战，并重点阐述了中国抗体以"全球首创（First-in-Class）与同类最优（Best-in-Class）"为核心的差异化创新策略。他详细介绍了公司核心产品SM17——一款靶向白细胞介素25（IL-25）受体的人源化单克隆抗体。SM17通过精准作用于II型免疫反应上游的关键"警戒素"分子IL-25受体，从源头抑制炎症级联反应，具有治疗特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉及特发性肺纤维化等多种炎症免疫性疾病的广阔潜力。梁博士分享了SM17在近期取得的一系列实质性进展：在AD领域，SM17的1b期临床研究显示出卓越的疗效，高剂量组91.7%的患者实现瘙痒缓解（NRS-4），75%达到皮损恢复（EASI 75），41.7%达到完全或近乎完全清除AD症状（IGA 0/1），疗效数据显著优于现有IL-4/IL-13类单抗，且安全性优于JAK抑制剂；基于此，SM17治疗中重度AD的II期临床试验已于2026年3月31日在中国完成首例患者给药，计划入组约210名患者，预计2026年下半年完成全部入组，2027年上半年获得顶线数据。在给药便利性方面，SM17皮下制剂的I期桥接研究于2026年3月25日取得积极顶线结果，30名健康受试者的数据显示皮下注射具有良好的安全性和药代动力学特征，仅有一例1级注射部位皮疹并自行消退，绝对生物利用度稳健，为后续开发更便捷的皮下给药方案奠定了基础。此外，SM17的适应症已成功拓展至IBD，其新药临床试验申请（IND）于2026年2月24日获中国国家药监局正式批准，涵盖克罗恩病及溃疡性结肠炎，相关桥接研究已于2026年2月完成，将直接推进至II期临床开发。梁博士还介绍了公司早期管线的创新布局：抗CGC抗体（全球首创人源化抗γc抗体）在治疗斑秃、白癜风等自身免疫性疾病中展现出潜力，计划于2026年第四季度提交IND申请；靶向RANKL及骨硬化蛋白的双特异性抗体在骨相关适应症的临床前研究中显示出优于现有上市药物的疗效，计划于2027年上半年提交IND申请。梁博士强调，中国抗体通过深耕创新靶点，逐步构建起具有协同效应的产品矩阵，旨在为全球患者提供更安全、更有效、更便捷的突破性治疗方案。此次受邀出席LifeArc转化科学峰会，不仅体现了国际权威机构对中国抗体创新研发实力与前沿探索的高度认可，也为公司深化全球合作提供了重要平台。通过与全球顶尖科学家、临床研究者及跨国药企高管的深入交流，中国抗体进一步拓展了国际学术网络与潜在合作渠道，为未来技术引进、联合研发、对外授权及商业化落地奠定了坚实基础。梁瑞安博士表示，公司将继续聚焦自身免疫性疾病领域未满足的临床需求，加速推进SM17等核心管线的全球多中心临床开发，同时积极探索运用人工智能等新技术赋能新靶点发现，并依托与中山大学香港高等研究院等机构的战略合作，强化从实验室到临床的转化能力。展望未来，中国抗体将把握中国生物医药对外授权高速增长的历史机遇，坚持差异化的全球创新路径，积极寻求与全球伙伴的多元化合作模式，推动创新成果更快惠及全球患者，为股东创造长期价值。关于中国抗体制药有限公司中国抗体制药有限公司（股份代号：03681.HK）是首创新药及潜在同类最佳抗体药物研发领域的开拓者，专注于自身免疫性疾病、以及由此导致的神经系统疾病及其他难治的耗损性疾病，致力于解决未被满足的医疗需求。中国抗体始终致力于开发针对全新靶点及通过创新机制的治疗性抗体，旨在现有疗法效果不佳的领域实现差异化临床成果。其丰富的研发管线包括：SM17在AD治疗中展现出卓越的止痒效果、皮肤清除率及安全性，同时在哮喘和特发性肺纤维化（IPF）领域具有应用潜力；其旗舰抗CD22舒西利单抗，除了临床验证对类风湿关节炎（RA）具有临床疗效外，目前正针对系统性红斑狼疮（SLE）和阿尔茨海默病开展临床评估；另一款抗CGC（共同γ链）创新单抗，正准备进入治疗斑秃和白癜风的临床研究；中国抗体亦研发了一款能同时刺激骨骼生长及抑制骨骼流失、治疗骨质疏松症的双特异性抗体。中国抗体以突破性疗效为核心追求，不断重新定义患者护理标准，稳居突破性疗法领域的领军地位。此新闻稿由真灼财经代中国抗体制药有限公司发布投资者及媒体查询联络人：Bunny LeeNomia ZhouQiuyan Deng电话：（852）5316 9995电邮：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeNomia ZhouQiuyan DengPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Anson Resources and POSCO Holdings have received board approval for a binding agreement to develop POSCO's Direct Lithium Extraction ("DLE") Demonstration Plant at the Green River Lithium Project in Utah.POSCO to lead the project at its own expense including the design, construction and operation of its proprietary Direct Lithium Extraction ("DLE") Demonstration PlantPOSCO to pay ~AUD $7.2 million (USD $5.2 million) non-dilutive facilitation fee to Anson.The collaboration positions Green River as a potential cornerstone asset in the emerging U.S. critical minerals and battery supply chain.During operation of the demonstration plant, the parties will evaluate broader commercial opportunities, including potential future joint investment and strategic cooperation.NEWPORT BEACH, CA, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson" or the "Company") is pleased to announce that both POSCO Holdings Inc. ("POSCO")'s board and the Company's board have approved the terms for a definitive Demonstration Plant Agreement ("Agreement") relating to the construction and operation of a Direct Lithium Extraction ("DLE") demonstration facility at the Green River Lithium Project in the Paradox Basin, Utah, USA.The board approvals mark a significant progression from the previously announced Memorandum of Understanding (see ASX Announcement 30 June 2025), establishing a framework under which POSCO will operate its own non-commercial DLE demonstration plant designed to validate lithium extraction at continuous industrial scale.Under the agreement POSCO committed to setting up its DLE demo-plant to extract lithium from brines produced from the Bosydaba #1 well owned by Anson at the Green River Lithium Project. POSCO will be responsible for engineering, construction, operation and maintenance of the facility, while Anson will provide access to property, infrastructure and brine supply. POSCO will pay Anson a non-dilutive facilitation fee of AUD ~$7.2 million (USD $5.2 million).The definitive agreement is expected to be signed before the end of Q2 2026. POSCO is expected to commence operation of the demonstration plant in 2027 and complete the work in 2028.The two companies will continue to explore potential business cooperation opportunities, including joint investment in the Project, during the operation of the demonstration plant, as outlined in the MoU Agreement, see ASX Announcement 30 June 2025.Strategic ImportanceDemonstrates strong industry validation of Green River's low-cost lithium potential.Accelerates technical de-risking through continuous demonstration-scale testing.Positions Green River as a key participant in the emerging U.S. domestic battery materials supply chain.Executive CommentaryExecutive Chairman & CEO, Mr. Bruce Richardson commented:"Securing a definitive agreement with POSCO represents a transformational step forward for the Green River Lithium Project.Moving from a non-binding MoU to a fully executed agreement underscores the strong technical confidence POSCO has in our asset and highlights the increasing strategic importance of domestic U.S. lithium supply."POSCO Holdings commented:"With the approval of the terms for a binding agreement, POSCO Holdings will advance validation of DLE technology in the United States and evaluate commercialisation pathways for future lithium production.We believe collaboration with Anson Resources at Green River will contribute to strengthening the North American lithium supply chain."Key Elements of the Definitive AgreementItemKey TermsProjectNon-commercial DLE Demonstration Plant - Green River Lithium ProjectResponsibilityPOSCO to bear cost for the design, construction, operations and maintenance for Demonstration PlantFacilitation FeeUSD $5.2MTermTo December 2028Brine SupplyProvided from Bosydaba #1 well with defined performance targetsAbout POSCO HoldingsPOSCO Holdings Inc. is a leading South Korean industrial group with strategic investments across steel, energy, and battery materials. POSCO Group is developing a global supply chain to support the transition EV and has invested in a total of 93,000 tonnes of lithium production annually in Argentina and South Korea. The company has made significant investments in both brine and hard-rock lithium resources across South America and Australia and is advancing proprietary Direct Lithium Extraction (DLE) technologies to accelerate low-carbon lithium production.This announcement has been authorized for release by the Executive Chairman and POSCO Holdings.For further information please contact:Bruce Richardson Will MazeExecutive Chairman and CEO Head of Investor RelationsE: info@Ansonresources.com E: investors@Ansonresources.comPh: +61 7 3132 7990 Ph: +61 7 3132 7990www.Ansonresources.com Follow us on Twitter @Anson_irSOURCE: Anson Resources Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com